Abstract
The R&D, regulatory, and marketing process in the pharmaceutical industry have distinct differences in timing, risk, opportunity, compliance, and cost structure compared to most other industries, making portions of portfolio decision analysis (PDA) significantly different. We will cover these differences and how PDA methods need to adapt to be most useful. We will address concepts of project valuation, portfolio prioritization, portfolio uncertainty, portfolio balance, and portfolio optimization. One goal of this chapter is to introduce the readers to concepts and methods which may not be used or even considered in their organizations, as well as to put the methods currently being used into context. We will present a methodology growing in popularity within PDA of discovery and early development portfolios– multiple objective decision analysis (MODA). A major theme throughout this chapter is a focus on portfolio objectives, rather than project goals, values, and risks. So many companies still focus their analytical efforts on project level valuation and prioritization, missing chances to help the organization meet portfolio level goals, fill company levels gaps, and help leaders conduct portfolio level risk management. We explore the idea that subportfolios exist, and different PDA methods may be more successfully implemented in one subportfolio than others. Finally, maximizing value, managing risk, and aligning decision making with company values requires an integrated portfolio management process, which we address at the end of the chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Drugs in Development: From Pipeline to Market 2010 PharmaLive, July 2010.
- 2.
K.S. Holland and B. Bátiz-Lazo, 2004 Case Study.
References
Belton V, Stewart T (2001) Multiple criteria decision analysis, Kluwer Academic Publishers
Buede D, Maxwell D (1995) Rank disagreement: a comparison of multi-criteria methodologies. J Multi-Criteria Decis Anal 4(1–2):1–21
Figueira J, Greco S, Ehrgott M (eds) (2005) Multiple criteria decision analysis. State of the art surveys. Springer, New York
Grelk B, Kloeber J, Jackson J, Parnell G, Deckro R (1998) Making the CERCLA criteria analysis of remedial alternatives more objective. Remediation 8(2):87–105
Howard R (1988) Decision analysis: practice and promise. Manage Sci 34(6):679–695
Keeney R (1992) Value focused thinking: a path to creative decision-making. Harvard University Press, Cambridge
Keeney R, Raiffa, H (1993) Decisions with multiple objectives, Cambridge books. Cambridge University Press, Cambridge
Keisler J (2004) Value of information in portfolio decision analysis. Decis Anal 1(3):177–189
Keisler J (2011) Portfolio decision quality. In: Salo A, Keisler J, Morton A (eds) Portfolio decision analysis: improved methods for resource allocation. Springer, New York
Matheson D, Matheson JE (1998) The smart organization. Harvard Business School Press, Boston
McNamee P, Celona J (1990) Decision Analysis with Supertree, Second edition. South San Francisco, California: The Scientific Press
Parnell GS, Bennett GE, Engelbrecht JA, Szafranski R (2002) Improving resource allocation within the national reconnaissance office. Interfaces 32(3):77–90
Salo A, Keisler J, Morton A (2011) An invitation to portfolio decision analysis. In: Salo A, Keisler J, Morton A (eds) Portfolio decision analysis: improved methods for resource allocation. Springer, New York
Sharpe P, Keelin T (1998) How SmithKline Beecham Makes Better Resource-Allocation Decisions, Harvard Business Review, March-April
Spilker B (2009) Guide to drug development: a comprehensive review and assessment. Lippicott, Williams and Wilkins, Philadelphia
Spradlin T, Kutolksi D (1999) Action-oriented portfolio Management. Res Technol Manage 42(2):26–32
U.S. Congress (2005) Congressional Base Realignment and Closure Act
U.S. Department of Homeland Security (2008) Bioterrorism risk assessment: a call for change, committee on methodological improvements to the Department of Homeland Security’s Biological Agent Risk Analysis. National Research Council National Academies Press
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kloeber, J. (2011). Current and Cutting Edge Methods of Portfolio Decision Analysis in Pharmaceutical R&D. In: Salo, A., Keisler, J., Morton, A. (eds) Portfolio Decision Analysis. International Series in Operations Research & Management Science, vol 162. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9943-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9943-6_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9942-9
Online ISBN: 978-1-4419-9943-6
eBook Packages: Business and EconomicsBusiness and Management (R0)